Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | DRD1 | P21728 | 3/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.57 |
| ▸ | HTR2B | P41595 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28404328 | 1.00 | ABCB11 (0.57) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL18845656 | 0.91 | ABCB11 (0.57) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL12723091 | 0.91 | ABCB11 (0.54) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL13575825 | 0.87 | ABCB11 (0.72) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL10999703 | 0.87 | ABCB11 (0.72) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL12723086 | 0.87 | ABCB11 (0.72) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL11001334 | 0.85 | ABCB11 (0.57) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL4770 | 0.83 | ABCB11 (0.77) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL19148650 | 0.83 | ABCB11 (0.77) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL14207882 | 0.83 | ABCB11 (0.57) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| EP-0099802-B1 | THIENO(3,2-C) PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USE | ELF SANOFI (FR) | 1987-02-04 | — | — | EP | claimed |
| US-10875874-B2 | Ginkgolide B derivative and preparation method and use thereof | CHENGDU BAIYU GINKGOLIDE PHARMACEUTICALS CO. LTD. (CN) | 2020-12-29 | — | — | US | disclosed |
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | disclosed |
| US-20190077811-A1 | Ginkgolide B Derivative and Preparation Method And Use Thereof | CHENGDU BAIYU GINKGOLIDE PHARMACEUTICALS CO., LTD. (CN) | 2019-03-14 | — | — | US | disclosed |
| US-7932391-B2 | Using halogen phenyl acetonitrile as starting material; tetrahydrothienopyridine (acetate or acetonitrile) as chemical intermediates; kinetic resolution; anticoagulant | Zhejiang Hauhai Pharmaceutical Co., Ltd. (CN) | 2011-04-26 | — | — | US | disclosed |
| US-20080249311-A1 | Using halogen phenyl acetonitrile as starting material; tetrahydrothienopyridine (acetate or acetonitrile) as chemical intermediates; kinetic resolution; anticoagulant | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2008-10-09 | — | — | US | disclosed |
| EP-1942110-A1 | PREPARATION OF CLOPIDOGREL AND ITS ANALOGUES METHYL TETRAHYDROTHIENOPYRIDINE ACETATE COMPOUNDS | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2008-07-09 | — | — | EP | disclosed |
| US-20050049415-A1 | Process for preparing enantiomerically pure alpha phenyl-alpha (6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)-acetic acid derivatives | MERCK GENERICS (UK) LIMITED (GB) | 2005-03-03 | — | — | US | disclosed |
| EP-1438314-A1 | A PROCESS FOR PREPARING ENANTIOMERICALLY PURE ALPHA-PHENYL-APLPHA(6,7-DIHYDRO-4H-THIENO 3,2-C PYRIDIN-5-YL)-ACETIC ACID DERIVATIVES | Merck Generics (UK) Limited (GB) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003035652-A1 | A PROCESS FOR PREPARING ENANTIOMERICALLY PURE α-PHENYL-α-(6,7-DIHYDRO-4H-THIENO[3,2-C]PYRIDIN-5-YL)-ACETIC ACID DERIVATIVES | MERCK GENERICS [UK] LIMITED (GB) | 2003-05-01 | — | — | WO | disclosed |
| US-4529596-A | Anticoagulant; clopidogrel (Methyl Alpha -(4,5,6,7-tetrahydro-thieno(3,2-c)-5-pyridyl)-o-chlorophenyl-acetate) | SANOFI, S.A. (FR) | 1985-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875874-B2 | Ginkgolide B derivative and preparation method and use thereof | GNB1, GYPA, GRK5 | ABCB11 217/4885CYP2C19 60/4885DRD1 1653/4885 |
| US-20080249311-A1 | Using halogen phenyl acetonitrile as starting material; tetrahydrothienopyridine (acetate or acetonitrile) as chemical intermediates; kinetic resolution; anticoagulant | TFPI, F2, CYP2C19 | ABCB11 539/4885CYP2C19 3/4885DRD1 546/4885 |
| US-20190077811-A1 | Ginkgolide B Derivative and Preparation Method And Use Thereof | GNB1, GYPA, GRK5 | ABCB11 217/4885CYP2C19 60/4885DRD1 1653/4885 |
| US-20050049415-A1 | Process for preparing enantiomerically pure alpha phenyl-alpha (6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)-acetic acid derivatives | NR1H3, NR1H2, NR1H4 | ABCB11 300/4885CYP2C19 124/4885DRD1 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.